Tom Strange
Private Equity Investor chez iCON Infrastructure LLP
Postes actifs de Tom Strange
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
iCON Infrastructure LLP
 iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Private Equity Investor | 01/06/2023 | - |
Historique de carrière de Tom Strange
Anciens postes connus de Tom Strange
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Private Equity Investor | 01/04/2022 | 01/11/2022 |
Formation de Tom Strange
| University of Cambridge | Graduate Degree |
| The University of Nottingham | Undergraduate Degree |
Statistiques
Internationale
| Royaume-Uni | 4 |
| Canada | 2 |
Opérationnelle
| Private Equity Investor | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
iCON Infrastructure LLP
iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Finance |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Tom Strange
- Expérience
